50 results about "Amphomycin" patented technology

Disclosed are compositions comprising a lipid polymer excipient and AmB or an AmB derivative. The lipid polymer excipient can form micelles when formulated with AmB or the AmB derivative and can solubilize and stabilize the drug. Also disclosed are methods of treating a fungal infection using the compositions.

The invention discloses an amplification culture solution of TILs cells and a culture method thereof. The amplification culture solution comprises a complete culture medium, and an anti-BTLA antibody with the final concentration of 0.1-10 [mu] g / mL, penicillin with the final concentration of 50-500 [mu] g / mL, streptomycin with the final concentration of 50-500 [mu] g / mL, gentamicin with the final concentration of 10-100 [mu] g / mL and amphotericin with the final concentration of 1-50 [mu] g / mL are added into the complete culture medium. The anti-BTLA antibody component in the culture solution can relieve inhibition of BTLA on T cells by blocking combination of BTLA and a ligand HVEM of BTLA, so that the anti-tumor capability of TILs is enhanced; meanwhile, after the BTLA is combined with the ligand HVEM, T cell activation and proliferation can be inhibited, and rapid proliferation of TILs is promoted; the irradiation PBMC added in the TILs cell culture process can provide an activation signal for the TILs and drive rapid proliferation of the TILs cells.

Provided are an amphotericin B amide derivative and a use thereof. The amphotericin B amide derivative is as shown in formula (I). The compound has good antifungal activity, is effective against various fungi, has good water solubility, is adapted to be developed into an injection dosage form, has excellent metabolic stability in animals (such as mice, rats, dogs, and monkeys), has a long half-life period, can effectively reduce the frequency of administration, has weak inhibition on CYP enzymes, and has a low risk of drug interaction.

The invention provides an amphotericin B amide derivative and application thereof. The amphotericin B amide derivative is shown as a formula (I), has good antifungal activity, is effective to various fungi, has good water solubility, is suitable for being developed into injections, has excellent metabolic stability in animal bodies (such as mice, rats, dogs and monkeys), is long in half-life period, can effectively reduce the administration frequency, is weak in CYP enzyme inhibition, and can be used for preparing the antifungal drugs. The drug interaction risk is low.

The invention relates to a process for obtaining an amphotericin B (AmB) formulation in liposomes containing dicetyl phosphate (DCP), based on incorporation of the drug into the membrane of preformed liposomes, combining the effects of pH on the solubility of amphotericin B and of temperature on the insertion of the drug into the liposome membrane. The technology also relates to use of the process and of the formulation for the manufacture of medicaments for the treatment of leishmaniasis and sporotrichosis, for oral or topical administration.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

Provided are a combination of an inositol phosphorylceramide synthase inhibitor and amphotericin B and use thereof. The use includes preparing a pharmaceutical composition, which includes an inositol phosphorylceramide synthetase inhibitor and amphotericin B or a salt thereof. Inositol phosphorylceramide is an important and conserved component of fungal plasma membranes. In the pharmaceutical composition according to an embodiment of the present disclosure, due to the presence of the inositol phosphorylceramide synthase inhibitor, the interaction between the inositol phosphorylceramide synthase inhibitor and amphotericin B not only enhances the inhibitory ability of the inositol phosphorylceramide synthase inhibitor on the synthesis of inositol phosphorylceramide in Cryptococcus, but also effectively reduces the dosage of amphotericin B and prolongs the half-life of amphotericin B, facilitating to reduce the adverse reactions of amphotericin B. The pharmaceutical composition exhibits superior fungicidal effect and safety compared to the currently used clinical combination of 5-fluorocytosine and amphotericin B.

The invention discloses a nano-robot based on tear driving, a preparation method of the nano-robot and application of the nano-robot in eye drops. The preparation method comprises the following steps: step 1, loading ophthalmic disease treatment drugs such as amphotericin B, voriconazole and natamycin into nano-particles such as polylactic acid-glycolic acid copolymer, chitosan and sodium alginate; 2, coupling urease on the surfaces of the nano-particles to obtain a nano-robot with autonomous movement ability; step 3, performing morphology characterization on the obtained nanometer robot driven by the tear liquid; and step 4, dispersing the prepared tear-driven nano-robot in a buffer solution to prepare the eye drops. The tear-driven nano-robot can utilize urea in tears as fuel to generate cluster motion on the cornea surface, so that the retention time is remarkably prolonged, the drug retention amount is increased, and the treatment effect is improved. The nano-robot eye drops based on tear driving have biocompatibility and treatment safety, and have wide application prospects in the field of ophthalmic local administration.

Disclosed is a simplified, readily scalable series of individual methods that collectively constitute a method for the synthesis of C2'epiAmB, an efficacious and reduced-toxicity derivative of amphotericin B (AmB), beginning from AmB. Also provided are various compounds corresponding to intermediates in accordance with the series of methods.

The present application relates to the use of amphotericin B or its combination in the preparation of anti-tumor drugs. The present application first confirms that amphotericin B directly binds to Toll-like receptor 2 and activates the downstream signaling pathway as a Toll-like receptor 2 agonist, thereby enhancing the phagocytic ability of macrophages to tumor cells; it is first confirmed that amphotericin B combined with therapeutic antibodies can produce a synergistic anti-tumor effect, and the above synergistic effect is mainly due to the regulatory effect of amphotericin B on macrophage function, including enhancing Fc gamma receptor expression and polarizing macrophages to M1 direction, which provides a solid foundation for the clinical transformation of amphotericin B and is expected to provide new treatment options for cancer patients.

This invention discloses a highly stable amphotericin B liposome and its preparation method, belonging to the field of pharmaceutical formulation technology. This invention utilizes a methanol-water-chloroform ternary mixed solvent system to achieve complete molecular-level dissolution of the raw materials, eliminating the conventional drying process and directly hydrating and homogenizing. It also provides optimal formulation ratios and process parameters. The preparation method includes steps such as oil phase preparation, aqueous phase preparation, homogenization, incubation, cooling, filtration, volumetric filling, and lyophilization. This invention creatively proposes optimal formulation composition and process conditions, resulting in a product with high encapsulation efficiency, uniform particle size, and strong stability. Furthermore, the preparation process is simple and easily industrialized, solving the problems of complex preparation processes and poor stability of existing injectable amphotericin B liposomes, and possesses good clinical application value.

The invention relates to the field of liposome manufacturing, and discloses an amphotericin B liposome and a preparation method thereof, and the amphotericin B liposome comprises the following components in parts by mass: 1 part of amphotericin B, 5-10 parts of hydrogenated soybean phospholipid (HSPC), 2-4 parts of cholesterol, 1-3 parts of mPEG2000-DSPE, 0.5-1.5 parts of ceramide, 0.3-0.8 part of glycyrrhetinic acid, 0.2-0.5 part of hydroxyapatite nanoparticles (nHAP) and 8-15 parts of a freeze-drying protective agent. The glycyrrhetinic acid is added, and the specific targeting effect of the glycyrrhetinic acid is utilized, so that the in-vitro binding rate of fungal cells of the lipidosome is improved, the enrichment rate of the medicine at an infected part is further improved, and the core problem of renal toxicity caused by non-targeting distribution of a traditional preparation is effectively solved; the hydroxyapatite nanoparticles adsorb medicine molecules to form a medicine-nHAP compound, and the medicine crystallization rate is greatly reduced by combining the synergistic anti-crystallization effect of the freeze-drying protective agent.

This application relates to the field of biotechnology, and particularly to primer pairs, primer-probe compositions, PCR premixes, kits, and methods for detecting multiple respiratory pathogens. Nucleic acid sequences are shown in primer pairs as indicated by SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38, and 40-41. For target respiratory pathogens, this application designs specific amplification primer pairs, paired with suitable probes, enabling the simultaneous detection of eight targets. Furthermore, the detection process avoids interference from heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, adrenaline, and lidocaine hydrochloride in the test sample. It exhibits good anti-interference properties and shows no cross-reactivity with *Rhodococcus equi*, *Candida tropicalis*, and *Candida krusei*.

This invention discloses a method for determining the encapsulation efficiency of amphotericin B liposomes for injection, comprising the following steps: separating the amphotericin B liposome solution for injection using solid-phase extraction adsorption to obtain an encapsulated drug solution and a free drug solution; and determining the drug mass concentration C in the encapsulated drug solution using HPLC. 包封 Drug mass concentration C in free drug solution 游离 And the total drug concentration C in the amphotericin B liposome solution before separation 总 The encapsulation efficiency and recovery rate of amphotericin B liposomes were calculated. This invention utilizes a macroporous copolymer of divinylbenzene and N-vinylpyrrolidone as the adsorbent in a solid-phase extraction adsorption method. Its macroporous structure provides ample adsorption sites while avoiding physical compression and damage to the liposome vesicles. This method achieves the separation of free amphotericin B liposomes from the encapsulated drug, exhibiting good reproducibility, high accuracy, simple operation, and high recovery rate.

This invention belongs to the field of organoid culture technology, specifically relating to a highly efficient organoid anticontamination reagent. This highly efficient organoid anticontamination reagent is composed of Primocin, amphotericin B, and Y-27632. In the organoid culture medium system, the final concentration of Primocin is 20-70 μg / mL, the final concentration of amphotericin B is 0.1-1 μg / mL, and the final concentration of Y-27632 is 5-20 μM. The highly efficient organoid anticontamination reagent provided by this invention exhibits dual high-efficiency inhibition against both bacteria and fungi, has a broad anticontamination spectrum, and is not prone to inducing microbial resistance. Simultaneously, it can reduce cytotoxicity, and long-term use does not alter the expression of organoid-specific markers, thus maintaining differentiation function.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The present invention relates to a pharmacotrophic ophthalmic composition comprising resveratrol, advantageously in an amount greater than 20 mg, for administration to a subject receiving anti-VEGF therapy.

The invention provides an amphotericin B hydrazide derivative and application thereof. The amphotericin B hydrazide derivative is shown as a formula (I). The compound disclosed by the invention has an obvious inhibition effect on the growth of candida albicans, aspergillus fumigatus and aspergillus flavus. (I).

Disclosed are therapeutic methods for treating a disease or condition characterized by decreased expression or reduced function of an ion channel using an amphotericin B derivative, or an amphotericin B derivative and an ion channel modulator. The methods can be used to treat cystic fibrosis.

The application discloses a kind of Vibration Mountain beard toad hind leg / toe tissue cells and its quick acquisition method and application.The method comprises: the body surface disinfection of Vibration Mountain beard individual, cut and take hind leg or toe tissue, and put back after wound disinfection;After tissue is soaked in 75% alcohol and washed with PBS containing penicillin, streptomycin and amphotericin B, it is temporarily stored in 4 ℃ temporary storage solution;After tissue is cut, it is sequentially digested with trypsin and type I collagenase;In the optimized low permeability medium, primary culture is carried out at 25-27 ℃;When cell confluence reaches 60%-70%, it is passaged using trypsin-EDTA digestion;Freezing and recovery.The application realizes the non-lethal cell of Vibration Mountain beard for the first time Quick acquisition, cell first time migration time is only 3 days, grow into monolayer only 12-17 days, pollution rate is reduced to 5.6%, recovery survival rate reaches 76.19%, and provides efficient and reliable technical support for endangered amphibian germplasm resource preservation and biological research.

The invention provides application of combined use of amphotericin B and sorafenib in preparation of a medicine for treating liver cancer. The invention also provides a pharmaceutical composition for treating liver cancer. The pharmaceutical composition is prepared from the following raw material medicines in parts by mass: 1-3 parts of amphotericin B and 1-10 parts of sorafenib. Pharmacodynamic tests prove that the amphotericin B and the sorafenib are combined to be used for treating the liver cancer, and the synergistic interaction effect is achieved.

The present invention provides a quaternary ammonium salt derivative of amphotericin B and a use thereof. The quaternary ammonium salt derivative of amphotericin B is as shown in formula (I), has good antifungal activity, is effective against various fungi, has good water solubility, is suitable for development into an injection dosage form, has excellent metabolic stability in animals and long half-life, can effectively reduce the frequency of administration, has weak inhibition on CYP enzymes, and has low risk of drug interaction.

The invention relates to the technical field of tissue engineering, and particularly discloses a pilose antler tissue cell culture method which comprises the following steps: S1, cell in-vitro culture; s2, directional induced differentiation; step S3, ossification induction; the induction culture medium 1, the induction culture medium 2 and the ossification induction culture medium are added, amphotericin B capable of covering the fungal pollution risk is added into the induction culture medium 1, fetal calf serum contained in the induction culture medium 1 can neutralize trypsin, recombinant human HGF contained in the induction culture medium 2 can improve the migration ability of cells, and meanwhile, the ossification induction culture medium can be used for preparing the ossification culture medium. The recombinant human bFGF can synergistically promote proliferation, so that emigrated cells are quickly accumulated, and the situation that the cell density is too low due to insufficient proliferation after emigration is avoided; ascorbic acid-2-phosphate contained in the ossification induction culture medium can avoid oxidation failure of ascorbic acid, and the cell emigration efficiency is improved through the synergistic effect of the substances.

This invention provides an electrospun gastric perforation patch based on Ag / Zn bimetallic MOF and its preparation method. The gastric perforation patch comprises a tissue integration layer, an antibacterial drug-loaded core layer, and an anti-adhesion layer integrally formed by electrospinning. The antibacterial drug-loaded core layer is composed of Ag / Zn bimetallic MOF loaded with antifungal drugs and a biodegradable polymer material. In the Ag / Zn bimetallic MOF, the molar ratio of zinc to silver is (8:1) to (12:1), and the antifungal drug is voriconazole or amphotericin B. This invention combines the broad-spectrum antimicrobial properties of Ag / Zn bimetallic MOF with a three-layer functional gradient design, enabling the patch to adhere firmly to tissue without sutures. It can actively prevent infection, inhibit adhesion, promote tissue regeneration, and gradually degrade and absorb postoperatively, significantly reducing the risk of foreign body reaction, infection, and recurrence, demonstrating excellent biocompatibility and broad clinical application prospects.

The invention provides a freezing transmission electron microscope detection method for amphotericin B liposome morphology, which comprises the steps of pretreating amphotericin B liposome, and freezing and imaging a pretreatment solution, the pretreatment comprises the following steps: redissolving with water to obtain a redissolving solution, and then dissolving with a disodium succinate solution and a 5% glucose solution to obtain the amphotericin B liposome morphology. And diluting to proper concentration step by step. The amphotericin B lipidosome pretreatment solution prepared by adopting the pretreatment method provided by the invention can ensure that the lipidosome is not broken or aggregated during freezing and imaging, can objectively reflect the real form of the medicine, and meets the research requirements of the type of preparation.

The invention belongs to the field of pharmaceutical preparations. The invention relates to a preparation method and application of probiotic coupled hyaluronic acid / chitosan oligosaccharide modified paclitaxel, amphotericin B and high-entropy nano-enzyme lipid nanoparticles. The prepared probiotic coupled lipid nanoparticles are good in biocompatibility, the preparation method is simple, the particle size distribution of the nanoparticles is uniform, chemotherapeutic drugs can be selectively enriched in tumor tissues, the treatment effect on cancers is remarkably enhanced by cooperating with a chemical kinetics therapy, and the probiotic coupled lipid nanoparticles have potential application value in the fields of cancer treatment and the like.

The invention belongs to the field of biological medicine, and discloses a pharmaceutical composition combining an aquaporin inhibitor and amphotericin B for treating brain glioma, and the pharmaceutical composition comprises an AQP4 inhibitor AER-270 and amphotericin B. The invention further discloses a pharmaceutical preparation containing the pharmaceutical composition and application of the pharmaceutical preparation to preparation of drugs for treating brain glioma. The tumor cell inhibition effect of the pharmaceutical composition provided by the invention is obviously better than that of single AER270 or amphotericin B, the pharmaceutical composition has an obvious synergistic effect, and an effective drug combination strategy is provided for treatment of brain glioma.

The invention relates to the technical field of drug impurity analysis, and discloses a method for detecting related substances of amphotericin B lipidosome. The amphotericin B lipidosome related substances comprise amphotericin B, an amphotericin impurity A, an amphotericin impurity B, an amphotericin impurity C, an amphotericin impurity D, an amphotericin impurity E, an amphotericin B glycosidic ligand and amphotericin B methyl ester, a mobile phase A of the liquid chromatography comprises a citric acid solution with the pH value of 4.7, acetonitrile and methanol, and a mobile phase B of the liquid chromatography comprises a mobile phase B of the liquid chromatography and a mobile phase B of the liquid chromatography; a mobile phase B of the liquid chromatography comprises a citric acid solution with the pH value of 3.9, acetonitrile and methanol. According to the method, the degree of separation of various amphotericin B liposome related substances is good, baseline separation is achieved, each impurity is attributed, a basis is provided for process research, tracking of the destination and trend of each impurity is facilitated, and stability research is further facilitated.

The invention relates to the technical field of biological medicine, in particular to amphotericin B liposome and a preparation method thereof.The preparation method comprises the steps that S1, amphotericin B, a film-forming material, an antioxidant and an acidified organic solvent are evenly mixed and dried to obtain fat powder; s2, the fat powder is subjected to hydration, homogenization, filtration, incubation and freeze drying in sequence; the incubation temperature is 60 to 70 DEG C, and the incubation time is 2 to 12 hours. The liposome prepared by the method provided by the invention is a round small single-chamber liposome with a uniform form; through detection, the amphotericin B lipid compound has the compounding rate of more than or equal to 99%, the particle size is small, the average particle size is less than or equal to 100nm, the particle size after redissolving is 50-150nm, the toxicity is low (the potassium release value is high), and the amphotericin B lipid compound can be prepared into low-toxicity freeze-dried powder injection for injection.